[ad_1]
However, other results have shown that the vaccine provides less protection against the highly contagious strain of the coronavirus, first identified in South Africa and now spreading rapidly around the world.
Novavax said it began developing new vaccines against emerging strains in early January and hopes to select ideal candidates in the coming days and launch clinical trials in the second quarter of this year.
“NVX-CoV2373 has the potential to play a key role in addressing this global public health crisis,” said Stanley Erck, CEO of the company, referring to the name of the Novavax vaccine.
“We want to continue working with our partners, collaborators, researchers and regulators around the world so that the vaccine is available as soon as possible,” he stressed.
British Prime Minister Boris Johnson wrote on Twitter that the published results are “good news.”
“Our drug regulator will now evaluate this vaccine, which will be produced at Tisaide. Yes [ji] It will be confirmed, we have asked for 60 million. dose, ”he added.
The vaccine is among six candidates endorsed by a US government project formerly known as Operation Warp Speed. According to him, the company received 1.75 billion. dollars (1,450 million euros). Vaccine trials are also underway in the United States and Mexico, where 16,000 people have been used. 30 thousand. Participants.
Unlike Pfizer, Moderna and AstraZeneca, vaccines that carry genetic instructions that force human cells to produce an important viral protein, Novavax is used to inject proteins directly into the body that elicit an immune response.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
